Lilly unites caring with discovery to create medicines that make life better for people around the world.

Since its inception in India in 1993, Eli Lilly and Company (India) Pvt. Ltd. has been committed to developing and marketing pharmaceutical products to treat diabetes, gastric cancer, lung cancer, breast cancer, osteoporosis, rheumatoid arthritis, men's health and growth-hormone deficiency.

At Lilly, saving and sustaining lives is our ultimate aim. In India, we are driven by a common vision and we are moving strongly and steadily towards it. Here is your opportunity to become a part of this bold vision, contribute to humanity and grow with a growing organization.

Apr 1, 2024 · American pharma major Eli Lilly sees India as its launchpad for a new growth trajectory, using its new drugs for diabetes and obesity as the fuel. Will this strategic pivot work?

Jan 10, 2025 · The Lilly Capability Centre India (LCCI), as the Hyderabad facility has been dubbed, will expand the company’s capabilities in automation, artificial intelligence, software product engineering...

Sep 23, 2024 · Eli Lilly and Company operates in India through two distinct business entities, expanding its pharmaceutical and drug development capabilities across the region. The company's operations extend beyond India, covering neighboring countries such as Nepal, Bangladesh, and Sri Lanka through distribution and promotion partnerships with local ...

Feb 28, 2024 · U.S. drugmaker Eli Lilly expects to launch Mounjaro, its blockbuster diabetes drug and a wildly popular obesity treatment, in India as early as next year, CEO David Ricks told Reuters on...

If you wish to report an adverse event or product complaint with a Lilly product, please call Lilly India on +91-124-4753000 (India) or 18001230021 or reach out to [email protected]. I am NOT a healthcare PROFESSIONAL

Eli Lilly and Company (India) Pvt. Ltd. (Lilly India), headquartered in Gurgaon, is a wholly owned subsidiary of Eli Lilly and Company, headquartered in Indianapolis, USA.

NEW DELHI and MUMBAI, India, July 29, 2011 /PRNewswire/ --. Eli Lilly India (Lilly) and Lupin Limited (Lupin)today announced they have entered into a strategic collaboration to promote and distribute Lilly's Huminsulin range of products, including Huminsulin R(TM), Huminsulin NPH(TM), Huminsulin 50/50(TM), Huminsulin 30/70(TM) and Humapen Ergo II. …